Eva M. D. C.
- Country
- Spain
- Department
- Oncology
Research Overview
- Comparative Study of Onivyde from Two Production Sites in Adults with Metastatic Pancreatic Adenocarcinoma
- Phase III Study of Rilvegostomig plus Combination Chemotherapy versus Durvalumab plus Combination Chemotherapy in Patients with Advanced Biliary Tract Cancer
- Switch Maintenance with Paclitaxel, Ramucirumab and Tislelizumab vs Continued Chemotherapy plus Tislelizumab in HER2‑negative, PD‑L1‑positive Gastroesophageal Adenocarcinoma
Data & Insights
Has run more than one trial at 157 of 278 partner sites.
Specializations
Pancreatic Cancer Research
This investigator demonstrates significant involvement in treating advanced pancreatic cancer, with particular focus on innovative therapeutic approaches. Their research encompasses metastatic pancreatic adenocarcinoma and novel treatment combinations including targeted therapies.
- VCN-01 therapy evaluation
- DNA damage repair targeted treatments
- KRAS mutation-specific therapies
Gastrointestinal Oncology
The investigator specializes in various gastrointestinal malignancies, including cholangiocarcinoma and gastric cancer. Their work extends to both early-stage and advanced disease states, incorporating novel therapeutic agents.
- Biliary tract cancer treatment
- Gastroesophageal junction cancers
- Microsatellite unstable tumors
Cancer-Associated Complications
The investigator addresses critical complications in cancer patients, particularly focusing on venous thromboembolism in oncology patients. Their research includes comparative studies of anticoagulation strategies in cancer-associated thrombosis.
- GI/GU cancer-related thrombosis
- Anticoagulation therapy evaluation
- Prevention of VTE recurrence
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.